Informationen: Dieses ist nicht die aktuellste Version des Datenmodells. Eine Versionsübersicht finden Sie links unter Versionen. Die aktuellste Version finden Sie hier.
Informationen:
Fehler:
ID
33553
Beschreibung
Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase; ODM derived from: https://clinicaltrials.gov/show/NCT01699217
Link
https://clinicaltrials.gov/show/NCT01699217
Stichworte
Versionen (2)
- 12.12.18 12.12.18 -
- 12.12.18 12.12.18 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
12. Dezember 2018
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Chronic Phase Philadelphia Positive NCT01699217
Eligibility Chronic Phase Philadelphia Positive NCT01699217
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Chronic Phase Philadelphia Positive NCT01699217
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Age
Item
age: >=18 years;
boolean
C0001779 (UMLS CUI [1])
CML Chronic-Phase Philadelphia chromosome positive | CML BCR/ABL positive
Item
patients with chronic phase ph+ and/or bcr-abl+ cml, newly diagnosed (less than 6 months);
boolean
C0023474 (UMLS CUI [1,1])
C0856536 (UMLS CUI [1,2])
C1292771 (UMLS CUI [2])
C0856536 (UMLS CUI [1,2])
C1292771 (UMLS CUI [2])
hydroxyurea | anagrelide
Item
prior treatment with hydroxyurea or anagrelide is allowed;
boolean
C0020402 (UMLS CUI [1])
C0051809 (UMLS CUI [2])
C0051809 (UMLS CUI [2])
imatinib
Item
prior treatment with im for less than 30 days is allowed;
boolean
C0935989 (UMLS CUI [1])
Informed Consent
Item
signed written informed const according to ich/eu/gcp and national local laws.
boolean
C0021430 (UMLS CUI [1])
Pregnancy | Pregnancy test negative Requested | Breast Feeding | Females & males of reproductive potential Contraceptive methods Absent
Item
patients who are pregnant (negative pregnancy test is requested within 2 days before nilotinib start) or breast feeding, or adults of reproductive potential not employing an effective method of birth control.
boolean
C0032961 (UMLS CUI [1])
C0427780 (UMLS CUI [2,1])
C1272683 (UMLS CUI [2,2])
C0006147 (UMLS CUI [3])
C4034483 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
C0427780 (UMLS CUI [2,1])
C1272683 (UMLS CUI [2,2])
C0006147 (UMLS CUI [3])
C4034483 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
Philadelphia chromosome positive CML Advanced phase | BCR/ABL positive CML Advanced phase | CML Accelerated Phase Philadelphia chromosome positive | Philadelphia chromosome positive CML Blastic Phase | BCR/ABL positive CML Accelerated phase | BCR/ABL positive CML Blastic Phase
Item
newly diagnosed ph+ and/or bcr-abl+ cml patients in advanced phases (accelerated or blastic phase).
boolean
C0279543 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1292771 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C0023472 (UMLS CUI [3,1])
C0856536 (UMLS CUI [3,2])
C0279543 (UMLS CUI [4,1])
C3899938 (UMLS CUI [4,2])
C1292771 (UMLS CUI [5,1])
C0457345 (UMLS CUI [5,2])
C1292771 (UMLS CUI [6,1])
C3899938 (UMLS CUI [6,2])
C0205179 (UMLS CUI [1,2])
C1292771 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C0023472 (UMLS CUI [3,1])
C0856536 (UMLS CUI [3,2])
C0279543 (UMLS CUI [4,1])
C3899938 (UMLS CUI [4,2])
C1292771 (UMLS CUI [5,1])
C0457345 (UMLS CUI [5,2])
C1292771 (UMLS CUI [6,1])
C3899938 (UMLS CUI [6,2])
nilotinib | dasatinib | Protein-tyrosine kinase inhibitor
Item
prior treatment with nilotinib, dasatinib, or other tyrosine-kinase inhibitors.
boolean
C1721377 (UMLS CUI [1])
C1455147 (UMLS CUI [2])
C1268567 (UMLS CUI [3])
C1455147 (UMLS CUI [2])
C1268567 (UMLS CUI [3])